Chemical Structure |
![]() |
Drug Class |
|
Mechanisms of Action |
Inhibits hepatic gluconeogenesis; reduces insulin resistance. Shows selective toxicity in metabolically active tumor cells via ROS induction and metabolic stress. |
Monograph |
Development: Introduced in the 1950s; withdrawn by 1978. Exhibited strong antidiabetic effect, but linked to lactic acidosis (~1 in 4,000 incidence). Lipophilic; accumulates in mitochondria; metabolized by CYP2D6. Modern Interest: Being re-evaluated as an anti-cancer compound with high mitochondrial selectivity. Represents a pharmacologically potent but clinically hazardous molecule. A high-risk, high-concept compound of enduring interest. |
Synthesis batch initiated |
|Amount acquired for synthesis: 2 g |Amount acquired for speculative holding: 0 mg Note: These figures reflect total documented acquisitions. Updated manually |
OrderBook |
Offer
Bid
|
Order via
(only to Europe, except UK, Denmark, and Austria.) |
|